Citations

Showing 10 of 108094 citations.

Predictors for cervical kyphotic deformity following laminoplasty: a systematic review and meta-analysis
Pettersson, Samuel D. , Skrzypkowska, Paulina , Ali, Shan , Krakowiak, Michał , Počivavšek, Tadej, Sunesson, Fanny, Fercho, Justyna , Miękisiak, Grzegorz, Ali, Shan , Szmuda, Tomasz , Miekisiak, Grzegorz Jerzy

Mayo Clinic

Journal of Neurosurgery: Spine | September 2, 2022 | Volume: 38 | Issue: 1 | Pages: 4-13

10.3171/2022.4.spine22182 | PMID 36057129 Get It

OBJECTIVE Laminoplasty is a common treatment for cervical spondylotic myelopathy (CSM) and for ossification of the posterior longitudinal ligament (OPLL). However, approximately 21% of patients undergoing laminoplasty develop cervical kyphotic deformity (KD). Because of the high prevalence rate of KD, several studies have sought to identify predictors for this complication, but the findings remain highly inconsistent. Therefore, the authors performed a systematic review and meta-analysis to establish reliable preoperative predictors of KD. METHODS PubMed, Scopus, and Web of Science databases were used to systematically extract potential references. The first phase of screening required the studies to be written in the English language, involve patients treated for CSM and/or OPLL via laminoplasty, and report postoperative cervical KD. The second phase required the studies to provide more than 10 patients and include a control group. The mean difference (MD) and odds ratio (OR) were calculated for continuous and dichotomous parameters. Study quality was evaluated using the Newcastle-Ottawa Scale. CSM and OPLL patients were further assessed by performing subgroup analyses. RESULTS Thirteen studies comprising patients who developed cervical KD (n = 296) and no KD (n = 1254) after receiving cervical laminoplasty for CSM or OPLL were included in the meta-analysis. All studies were retrospective cohorts and were rated as high quality. In the combined univariate analysis of CSM and OPLL patients undergoing laminoplasty, statistically significant predictors for postoperative KD included age (MD 2.22, 95% CI 0.16–4.27, p = 0.03), preoperative BMI (MD 0.85, 95% CI 0.06–1.63, p = 0.04), preoperative C2–7 range of flexion (MD 10.42, 95% Cl 4.24–16.59, p = 0.0009), preoperative C2–7 range of extension (MD −4.59, 95% CI −6.34 to −2.83, p < 0.00001), and preoperative center of gravity of the head to the C7 sagittal vertical axis (MD 26.83, 95% CI 9.13–44.52, p = 0.003). Additionally, among CSM patients, males were identified as having a greater risk for postoperative KD (OR 1.73, 95% CI 1.02–2.93, p = 0.04). CONCLUSIONS The findings from this study currently provide the largest and most reliable review on preoperative predictors for cervical KD after laminoplasty. Given that several of the included studies identified optimal cutoff points for the variables that are significantly associated with KD, further investigation into the development of a preoperative risk scoring system that can accurately predict KD in the clinical setting is encouraged. PROSPERO registration no.: CRD42022299795 ( https://www.crd.york.ac.uk/PROSPERO/ ).
Characterization of Morreton virus as an oncolytic virotherapy platform for liver cancers
Nagalo, Bolni Marius , Zhou, Yumei , Loeuillard, Emilien , Dumbauld, Chelsae, Barro, Oumar, Elliott, Natalie , Baker, Alexander T. , Arora, Mansi , Meurice, Nathalie , Aslam, Faaiq , Gabere, Musa , Basnakian, Alexei G. , Simões, Camila , Cannon, Martin J. , Buetow, Kenneth H. , Barrett, Michael T. , Duda, Dan G. , Jacobs, Bertram , Vile, Richard G. , Barry, Michael A. , Roberts, Lewis R. , Loeuillard, Emilien J, Elliott, Natalie , Bogenberger, James M. , Petit, Joachim, Uson, Pedro L S , Raupach, Elizabeth, Chamcheu, Jean Christopher , Duda, Dan G , Ilyas, Sumera Irie , Roberts, Lewis R , Barry, Michael A , Nagalo, Bolni , Baker, Alexander , Aslam, Faaiq N , Petit, Joachim L. , Usón, Pedro Luiz Serrano , Raupach, Elizabeth A. , Post, Steven R. , Ilyas, Sumera I. , Borad, Mitesh J.

Mayo Clinic

Hepatology | September 2, 2022 | Volume: 77 | Issue: 6 | Pages: 1943-1957

10.1002/hep.32769 | PMID 36052732 Get It

Background: Morreton virus (MORV) is an oncolytic Vesiculovirus , genetically distinct from vesicular stomatitis virus (VSV). Aim: To report that MORV induced potent cytopathic effects (CPEs) in cholangiocarcinoma (CCA) and hepatocellular carcinoma (HCC) in vitro models. Approach and Results: In preliminary safety analyses, high intranasal doses (up to 10 10 50% tissue culture infectious dose [TCID 50 ]) of MORV were not associated with significant adverse effects in immune competent, non–tumor‐bearing mice. MORV was shown to be efficacious in a Hep3B hepatocellular cancer xenograft model but not in a CCA xenograft HuCCT1 model. In an immune competent, syngeneic murine CCA model, single intratumoral treatments with MORV (1 × 10 7 TCID 50 ) triggered a robust antitumor immune response leading to substantial tumor regression and disease control at a dose 10‐fold lower than VSV (1 × 10 8 TCID 50 ). MORV led to increased CD8 + cytotoxic T cells without compensatory increases in tumor‐associated macrophages and granulocytic or monocytic myeloid‐derived suppressor cells. Conclusions: Our findings indicate that wild‐type MORV is safe and can induce potent tumor regression via immune‐mediated and immune‐independent mechanisms in HCC and CCA animal models without dose limiting adverse events. These data warrant further development and clinical translation of MORV as an oncolytic virotherapy platform.
Renal denervation in the antihypertensive arsenal – knowns and known unknowns
Brguljan, Jana , Ferdinand, Keith C. , Laffer, Cheryl L. , Ram, C. Venkata S. , Shalaeva, E. , Textor, Stephen C., Vongpatanasin, Wanpen , Vogt, Liffert , Wang, Ji‐Guang , Williams, Bryan , Messerli, Franz H. , Bavishi, Chirag , Burnier, Michel , Dobner, Stephan , Elijovich, Fernando , Kjeldsen, Sverre Erik , Rexhaj, Emrush , Ruilope, Luis Miguel , Siontis, George C.M. , Staessen, Jan A , Volpe, Massimo

Mayo Clinic

Journal of Hypertension | September 2, 2022 | Volume: 40 | Issue: 10 | Pages: 1859-1875

10.1097/hjh.0000000000003171 | PMID 36052518 Get It

Even though it has been more than a decade since renal denervation (RDN) was first used to treat hypertension and an intense effort on researching this therapy has been made, it is still not clear how RDN fits into the antihypertensive arsenal. There is no question that RDN lowers blood pressure (BP), it does so to an extent at best corresponding to one antihypertensive drug. The procedure has an excellent safety record. However, it remains clinically impossible to predict whose BP responds to RDN and whose does not. Long-term efficacy data on BP reduction are still unconvincing despite the recent results in the SPYRAL HTN-ON MED trial; experimental studies indicate that reinnervation is occurring after RDN. Although BP is an acceptable surrogate endpoint, there is complete lack of outcome data with RDN. Clear indications for RDN are lacking although patients with resistant hypertension, those with documented increase in activity of the sympathetic system and perhaps those who desire to take fewest medication may be considered.
Classifying Refugee Status Using Common Features in EMR**
Morrison, Malia, Nobles, Vanessa, Bailey, Celeste , Liu, Li , Liu, Li , Johnson‐Agbakwu, Crista E.

Mayo Clinic

Chemistry & Biodiversity | September 2, 2022 | Volume: 19 | Issue: 10 | Pages: No page available

10.1002/cbdv.202200651 | PMID 36050919 Get It

Abstract Automated and accurate identification of refugees in healthcare databases is a critical first step to investigate healthcare needs of this vulnerable population and improve health disparities. In this study, we developed a machine‐learning method, named refugee identification system (RIS) to address this need. We curated a data set consisting of 103 refugees and 930 non‐refugees in Arizona. We compiled de‐identified individual‐level information including age, primary language, and noise‐masked home address, state‐level refugee resettlement statistics, and world language statistics. We then performed feature engineering to convert language and masked address into quantitative features. Finally, we built a random forest model to classify refugee and non‐refugees. RIS achieved high classification accuracy (overall accuracy=0.97, specificity=0.99, sensitivity=0.85, positive predictive value=0.88, negative predictive value=0.98, and area under receiver operating characteristic curve=0.98). RIS is customizable for refugee identification outside Arizona. Its application enables large‐scale investigation of refugee healthcare needs and improvement of health disparities.
Quality of Life and Cognitive Function Evaluations and Interventions for Patients with Brain Metastases in the Radiation Oncology Clinic
Matsui, Jennifer K. , Perlow, Haley K. , Baiyee, Cyril, Ritter, Alex R., Mishra, Mark V. , Bovi, Joseph , Gondi, Vinai , Brown, Paul D. , Leeper, Heather , Dawson, Erica , Palmer, Joshua D. , Bovi, Joseph A , Leeper, Heather E , Dawson, Erica , Palmer, Joshua D , Mishra, Mark V , Perlow, Haley K , Loughan, Ashlee R.

Mayo Clinic

Cancers | September 1, 2022 | Volume: 14 | Issue: 17 | Pages: 4301

10.3390/cancers14174301 | PMID 36077835 Get It

Brain metastases (BMs) account for a disproportionately high percentage of cancer morbidity and mortality. Historically, studies have focused on improving survival outcomes, and recent radiation oncology clinical trials have incorporated HRQOL and cognitive assessments. We are now equipped with a battery of assessments in the radiation oncology clinic, but there is a lack of consensus regarding how to incorporate them in modern clinical practice. Herein, we present validated assessments for BM patients, current recommendations for future clinical studies, and treatment advances that have improved HRQOL and cognitive outcomes for BM patients.
A Treatment Paradigm Shift: Targeted Radionuclide Therapies for Metastatic Castrate Resistant Prostate Cancer
Parent, Ephraim E. , Kase, Adam M. , Parent, Ephraim E

Mayo Clinic

Cancers | September 1, 2022 | Volume: 14 | Issue: 17 | Pages: 4276

10.3390/cancers14174276 | PMID 36077820 Get It

The recent approval of 177Lu PSMA-617 (Pluvicto®) by the United States Food and Drug Administration (FDA) is the culmination of decades of work in advancing the field of targeted radionuclide therapy for metastatic prostate cancer. 177Lu PSMA-617, along with the bone specific radiotherapeutic agent, 223RaCl2 (Xofigo®), are now commonly used in routine clinical care as a tertiary line of therapy for men with metastatic castrate resistant prostate cancer and for osseus metastatic disease respectively. While these radiopharmaceuticals are changing how metastatic prostate cancer is classified and treated, there is relatively little guidance to the practitioner and patient as to how best utilize these therapies, especially in conjunction with other more well-established regimens including hormonal, immunologic, and chemotherapeutic agents. This review article will go into detail about the mechanism and effectiveness of these radiopharmaceuticals and less well-known classes of targeted radionuclide radiopharmaceuticals including alpha emitting prostate specific membrane antigen (PSMA)-, gastrin-releasing peptide receptor (GRPR)-, and somatostatin targeted radionuclide therapeutics. Additionally, a thorough discussion of the clinical approach of these agents is included and required futures studies.
iBreastExam: Time for Formal Operation in Nepal
Kharel, Sanjeev , Shrestha, Suraj , Yadav, Siddhartha , Yadav, Siddhartha

Mayo Clinic

JCO Global Oncology | September 1, 2022 | Volume: No volume available | Issue: 8 | Pages: No page available

10.1200/go.22.00216 | PMID 36049152 Get It

Acoustic Force Elastography Microscopy
Liu, Hsiao‐Chuan , Gaihre, Bipin , Kijanka, Piotr , Lu, Lichun , Urban, Matthew W. , Urban, Matthew W

Mayo Clinic

IEEE Transactions on Biomedical Engineering | September 1, 2022 | Volume: 70 | Issue: 3 | Pages: 841-852

10.1109/tbme.2022.3203435 | PMID 36049008 Get It

Exogenous pericyte delivery protects the mouse kidney from chronic ischemic injury
Song, Turun , Zhu, Xiangyang , Eirin, Alfonso , Jiang, Yamei , Krier, James D., Jordan, Kyra L., Lerman, Lilach O. , Eirin, Alfonso , Tang, Hui Ru , Lerman, Amir

Mayo Clinic

American Journal of Physiology-Renal Physiology | September 1, 2022 | Volume: 323 | Issue: 5 | Pages: F527-F538

10.1152/ajprenal.00064.2022 | PMID 36049063 Get It

Our study demonstrates a novel pericyte-based therapy for the injured kidney. The beneficial effect of pericyte delivery appears to be mediated by ameliorating oxidative stress, inflammation, cellular apoptosis, and senescence in the stenotic kidney and improved tissue hypoxia, vascular loss, fibrosis, and tubular atrophy. Our data may form the basis for pericyte-based therapy, and additional research studies are needed to gain further insight into their role in improving renal function.
Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022)
Bhimraj, Adarsh , Shumaker, Amy Hirsch, Baden, Lindsey R. , Edwards, Kathryn M. , Gallagher, Jason C , Gandhi, Rajesh T. , Nakamura, Mari , Sultan, Shahnaz , Falck–Ytter, Yngve , Morgan, Rebecca L. , Cheng, Vincent Chi‐Chung , Muller, William J. , O’Horo, John C. , Shafer, Robert W. , Shoham, Shmuel , Murad, M. Hassan , Mustafa, Reem A

Mayo Clinic

Clinical Infectious Diseases | September 1, 2022 | Volume: 78 | Issue: 7 | Pages: e250-e349

10.1093/cid/ciac724 | PMID 36063397 Get It

Abstract There are many pharmacologic therapies that are being used or considered for treatment of coronavirus disease 2019 (COVID-19), with rapidly changing efficacy and safety evidence from trials. The objective was to develop evidence-based, rapid, living guidelines intended to support patients, clinicians, and other healthcare professionals in their decisions about treatment and management of patients with COVID-19. In March 2020, the Infectious Diseases Society of America (IDSA) formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise to regularly review the evidence and make recommendations about the treatment and management of persons with COVID-19. The process used a living guideline approach and followed a rapid recommendation development checklist. The panel prioritized questions and outcomes. A systematic review of the peer-reviewed and grey literature was conducted at regular intervals. The Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. Based on the most recent search conducted on 31 May 2022, the IDSA guideline panel has made 32 recommendations for the treatment and management of the following groups/populations: pre- and postexposure prophylaxis, ambulatory with mild-to-moderate disease, and hospitalized with mild-to-moderate, severe but not critical, and critical disease. As these are living guidelines, the most recent recommendations can be found online at: https://idsociety.org/COVID19guidelines. At the inception of its work, the panel has expressed the overarching goal that patients be recruited into ongoing trials. Since then, many trials were conducted that provided much-needed evidence for COVID-19 therapies. There still remain many unanswered questions as the pandemic evolved, which we hope future trials can answer.